Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NVDQ's Cash to Debt is ranked higher than
90% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. NVDQ: No Debt )
NVDQ' s 10-Year Cash to Debt Range
Min: 0.72   Max: No Debt
Current: No Debt

Equity to Asset 0.83
NVDQ's Equity to Asset is ranked higher than
86% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. NVDQ: 0.83 )
NVDQ' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.96
Current: 0.83

-0.06
0.96
F-Score: 5
Z-Score: 14.96
M-Score: -1.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -20.67
NVDQ's Operating margin (%) is ranked higher than
58% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. NVDQ: -20.67 )
NVDQ' s 10-Year Operating margin (%) Range
Min: -1278.97   Max: -13.33
Current: -20.67

-1278.97
-13.33
Net-margin (%) -63.68
NVDQ's Net-margin (%) is ranked higher than
53% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. NVDQ: -63.68 )
NVDQ' s 10-Year Net-margin (%) Range
Min: -1103.37   Max: -53.7
Current: -63.68

-1103.37
-53.7
ROE (%) -12.74
NVDQ's ROE (%) is ranked higher than
59% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. NVDQ: -12.74 )
NVDQ' s 10-Year ROE (%) Range
Min: -1621.88   Max: -12.74
Current: -12.74

-1621.88
-12.74
ROA (%) -10.50
NVDQ's ROA (%) is ranked higher than
58% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. NVDQ: -10.50 )
NVDQ' s 10-Year ROA (%) Range
Min: -115.15   Max: -10.5
Current: -10.5

-115.15
-10.5
ROC (Joel Greenblatt) (%) -40.82
NVDQ's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. NVDQ: -40.82 )
NVDQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1717.24   Max: -26.17
Current: -40.82

-1717.24
-26.17
Revenue Growth (%) 13.20
NVDQ's Revenue Growth (%) is ranked higher than
88% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. NVDQ: 13.20 )
NVDQ' s 10-Year Revenue Growth (%) Range
Min: -1.4   Max: 132.1
Current: 13.2

-1.4
132.1
EBITDA Growth (%) -1.70
NVDQ's EBITDA Growth (%) is ranked higher than
68% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. NVDQ: -1.70 )
NVDQ' s 10-Year EBITDA Growth (%) Range
Min: -26.9   Max: 80.8
Current: -1.7

-26.9
80.8
EPS Growth (%) -3.30
NVDQ's EPS Growth (%) is ranked higher than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. NVDQ: -3.30 )
NVDQ' s 10-Year EPS Growth (%) Range
Min: -22.2   Max: 75.3
Current: -3.3

-22.2
75.3
» NVDQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

NVDQ Guru Trades in Q1 2013

Prem Watsa 2,358,487 sh (+17.92%)
» More
Q2 2013

NVDQ Guru Trades in Q2 2013

Chuck Royce 79,279 sh (New)
Prem Watsa Sold Out
» More
Q3 2013

NVDQ Guru Trades in Q3 2013

Chuck Royce 135,000 sh (+70.28%)
» More
Q4 2013

NVDQ Guru Trades in Q4 2013

Ron Baron 13,330 sh (New)
Chuck Royce 135,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NVDQ

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-12-31 New Buy$15.67 - $18.719 $ 16.992%13330
Prem Watsa 2013-06-30 Sold Out 0.87%$9.93 - $14.76 $ 16.9932%0
Prem Watsa 2013-03-31 Add 17.92%0.13%$8.74 - $11.42 $ 16.9974%2358487
Prem Watsa 2012-12-31 New Buy0.69%$8.42 - $11.94 $ 16.9970%2000000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.50
NVDQ's P/B is ranked lower than
64% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. NVDQ: 5.50 )
NVDQ' s 10-Year P/B Range
Min: 5.03   Max: 30.48
Current: 5.5

5.03
30.48
P/S 22.80
NVDQ's P/S is ranked lower than
78% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. NVDQ: 22.80 )
NVDQ' s 10-Year P/S Range
Min: 6.65   Max: 29.62
Current: 22.8

6.65
29.62
EV-to-EBIT 14.70
NVDQ's EV-to-EBIT is ranked higher than
70% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. NVDQ: 14.70 )
NVDQ' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 14.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.40
NVDQ's Price/Net Cash is ranked higher than
62% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. NVDQ: 6.40 )
NVDQ' s 10-Year Price/Net Cash Range
Min: 6.25   Max: 29.6
Current: 6.4

6.25
29.6
Price/Net Current Asset Value 6.10
NVDQ's Price/Net Current Asset Value is ranked higher than
70% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. NVDQ: 6.10 )
NVDQ' s 10-Year Price/Net Current Asset Value Range
Min: 5.89   Max: 22.2
Current: 6.1

5.89
22.2
Price/Tangible Book 5.40
NVDQ's Price/Tangible Book is ranked lower than
54% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NVDQ: 5.40 )
NVDQ' s 10-Year Price/Tangible Book Range
Min: 5.27   Max: 12.16
Current: 5.4

5.27
12.16
Price/DCF (Projected) 32.10
NVDQ's Price/DCF (Projected) is ranked lower than
76% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. NVDQ: 32.10 )
NVDQ' s 10-Year Price/DCF (Projected) Range
Min: 31.71   Max: 31.71
Current: 32.1

Price/Median PS Value 1.20
NVDQ's Price/Median PS Value is ranked higher than
54% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. NVDQ: 1.20 )
NVDQ' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 1.25
Current: 1.2

0.38
1.25
Forward Rate of Return (Yacktman) -18.44
NVDQ's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. NVDQ: -18.44 )
NVDQ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 18.7   Max: 19
Current: -18.44

18.7
19

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NDQ.Canada, NQT.Germany
Novadaq Technologies Inc., was incorporated under the Canada Business Corporations Act on April 14, 2000. The company develops, manufactures and markets real-time fluorescence imaging technology products that are designed for use by surgeons in the operating room and other clinical settings where open, minimally invasive or interventional surgical procedures are performed. The Company's SPY imaging core technology platform provides clinically relevant anatomic and physiologic images during a variety of complex surgical procedures performed in the operating room and outpatient surgery center without exposing the patient or the surgery staff to radiation. The SPY technology platform is flexible and can be used to develop unique imaging devices specifically designed to meet the needs of different surgeons and the specialty procedures they perform. SPY images enable surgeons treating life-threatening illnesses, such as breast, head and neck, colon, kidney and other cancers, complex hernias, diabetes and certain cardiovascular diseases, to effectively visualize blood flow in vessels, co-joined vessels and micro-vessels and to visually assess the quality of blood perfusion in tissue such as skin and organs. In addition to marketing SPY imaging technology products, the Company acquired and now manufactures and markets the FDA Premarket Approval approved CO2 Heart LaserTM system for Transmyocardial Revascularization.
» More Articles for NAS:NVDQ

Headlines

Articles On GuruFocus.com
Prem Watsa Increases NYT and Two Others May 15 2013 
comment on NVDQ Mar 03 2013 
Prem Watsa Increases Novadaq Technologies Ownership to 6.6 Pct Feb 14 2013 

More From Our Partners
TauTona Group Sells Aline HA to Allergan Apr 17 2014 - BENZINGA

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide